Cassava Sciences Stock Income Statements

Cassava Sciences Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

Cassava Sciences Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2015-12-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-05-04	2002-05-04	2002-05-04

operating expenses:
research and development	5,116,000	13,666,000	12,276,750	17,676,000	15,198,000	16,233,000																			436,000		1,108,000	2,116,000	1,935,000	2,147,000	1,151,000	1,444,000	1,139,000	1,183,000	2,101,000	2,379,000	1,516,000	1,609,000	1,711,000	2,019,000	2,392,000	2,178,000	8,010,000	2,360,000	2,248,000	3,127,000	3,812,000	4,521,000	5,090,000	7,636,000	9,190,000	12,928,000	11,215,000	12,484,000	13,559,000	13,268,000	11,044,000	9,860,000	13,290,000	10,471,000	10,188,000	12,854,000	7,155,000	8,144,000	9,518,000	8,122,000	67,709,000	8,547,000	8,181,000	9,496,000	45,979,000	5,358,000	3,715,000	43,715,000
general and administrative	40,276,000	10,920,000	8,957,000	12,947,000	46,204,000	3,701,000	4,058,000	4,276,000	3,808,000	4,392,000	3,285,000	2,819,000	2,969,000	2,915,000	4,102,000	1,712,000	1,237,000	1,004,000	1,038,000	818,000	778,000	831,000	845,000	877,000	848,000		1,059,000	1,429,000	1,322,000	1,317,000	1,190,000	1,290,000	1,139,000	1,218,000	2,207,000	2,001,000	1,461,000	1,512,000	1,620,000	1,753,000	1,788,000	1,537,000	9,510,000	2,107,000	1,663,000	1,486,000	1,583,000	1,530,000	1,414,000	1,731,000	1,927,000	3,552,000	1,896,000	1,819,000	2,134,000	2,011,000	2,102,000	1,838,000	1,962,000	1,686,000	2,049,000	1,970,000	1,577,000	1,105,000	1,139,000	1,038,000	23,998,000	861,000	1,106,000	937,000	20,578,000	735,000	751,000	20,667,000
total operating expenses	45,392,000	24,586,000	29,487,000	30,623,000	61,402,000	19,934,000	22,789,000	27,879,000	28,777,000	26,512,000	20,937,000	21,345,000	19,917,000	17,821,000	14,444,000	9,753,000	5,138,000	3,533,000	1,437,000	1,163,000	1,222,000	779,000	1,153,000	1,451,000	1,284,000		2,167,000	3,545,000	3,257,000	3,464,000	2,341,000	2,734,000	2,278,000	2,401,000	4,308,000	4,380,000	2,977,000	3,121,000	3,331,000	3,772,000	4,180,000	3,715,000	17,520,000	4,467,000	3,911,000	4,613,000	5,395,000	6,051,000	6,504,000	9,367,000	11,117,000	16,480,000	13,111,000	14,303,000	15,693,000	15,279,000	13,146,000	11,698,000	15,252,000	12,157,000	12,237,000	14,824,000	8,732,000	9,249,000	10,657,000	9,160,000	91,707,000	9,408,000	9,287,000	10,433,000	66,557,000	6,093,000	4,466,000		51,002,887	51,002,887
operating income	-45,392,000	-24,586,000	-29,487,000	-30,623,000	-61,402,000	-19,934,000	-22,789,000	-27,879,000	-28,777,000	-26,512,000	-20,937,000	-21,345,000	-19,917,000	-17,821,000	-14,444,000	-9,753,000	-5,138,000	-3,533,000	-1,437,000	-1,163,000	-1,222,000	-779,000	-1,153,000	-1,451,000	-1,284,000		-2,167,000	-3,545,000	-3,257,000	-3,464,000	32,903,000	-776,000	-319,000	-443,000	-1,840,000	-1,655,000	-253,000	-148,000	-584,000	-1,023,000	-1,428,000	-479,000	-9,511,000	-1,572,000	-1,255,000	-1,364,000	-1,666,000	-2,288,000	-268,000	-2,532,000	-2,873,000	13,814,000	-2,564,000	336,000	-1,637,000	531,000	919,000	10,356,000	-8,916,000	6,353,000	1,509,000	502,000	-3,652,000	-9,249,000	-10,657,000	-9,160,000	-91,707,000	-9,408,000	-9,287,000	-10,433,000	-66,557,000	-6,093,000	-4,466,000		-51,002,887	-51,002,887
yoy	-26.07%	23.34%	29.39%	9.84%	113.37%	-24.81%	8.85%	30.61%	44.48%	48.77%	44.95%	118.86%	287.64%	404.42%	905.15%	738.61%	320.46%	353.53%	24.63%	-19.85%	-4.83%		-46.79%	-59.07%	-60.58%		-106.59%	356.83%	921.00%	681.94%	-1888.21%	-53.11%	26.09%	199.32%	215.07%	61.78%	-82.28%	-69.10%	-93.86%	-34.92%	13.78%	-64.88%	470.89%	-31.29%	368.28%	-46.13%	-42.01%	-116.56%	-89.55%	-853.57%	75.50%	2501.51%	-379.00%	-96.76%	-81.64%	-91.64%	-39.10%	1962.95%	144.14%	-168.69%	-114.16%	-105.48%	-96.02%	-1.69%	14.75%	-12.20%	37.79%	54.41%	107.95%		30.50%	-88.05%
qoq	84.63%	-16.62%	-3.71%	-50.13%	208.03%	-12.53%	-18.26%	-3.12%	8.54%	26.63%	-1.91%	7.17%	11.76%	23.38%	48.10%	89.82%	45.43%	145.86%	23.56%	-4.83%	56.87%	-32.44%	-20.54%	13.01%			-38.87%	8.84%	-5.98%	-110.53%	-4340.08%	143.26%	-27.99%	-75.92%	11.18%	554.15%	70.95%	-74.66%	-42.91%	-28.36%	198.12%	-94.96%	505.03%	25.26%	-7.99%	-18.13%	-27.19%	753.73%	-89.42%	-11.87%	-120.80%	-638.77%	-863.10%	-120.53%	-408.29%	-42.22%	-91.13%	-216.15%	-240.34%	321.01%	200.60%	-113.75%	-60.51%	-13.21%	16.34%	-90.01%	874.78%	1.30%	-10.98%	-84.32%	992.35%	36.43%
operating margin %																															93.36%	-39.63%	-16.28%	-22.63%	-74.55%	-60.73%	-9.29%	-4.98%	-21.26%	-37.21%	-51.89%	-14.80%	-118.75%	-54.30%	-47.25%	-41.98%	-44.68%	-60.80%	-4.30%	-37.04%	-34.85%	45.60%	-24.31%	2.30%	-11.65%	3.36%	6.53%	46.96%	-140.72%	34.32%	10.98%	3.28%
interest income	1,214,000	1,265,000	1,800,000	2,618,000	2,316,000	1,776,000	1,579,000	2,005,000	2,198,000	2,051,000	1,554,000	878,000	314,000	31,000	14,000	15,000	13,000	7,000	7,000	27,000	72,000	82,000	94,000	92,000	17,000		11,000	11,000	11,000	14,000	16,750	14,000	18,000	35,000	101,250	105,000	123,000	178,000	177,000	208,000	228,000	272,000	335,000	544,000	451,000	344,000	308,250	613,000	233,000	387,000	1,287,750	1,377,000	1,539,000	2,234,000													167,000	177,000	221,000	270,000	7,241,000	124,000	120,000	7,134,000
other income	-46,000	-82,000	90,000	62,000	99,000	160,000	291,000	223,000	203,000	190,000	249,000	210,000	275,000	263,000	258,000	176,000																																																											0.00%	0.00%
gain from change in fair value of warrant liabilities					65,142,000	43,041,000
net income	-44,224,000	-23,403,000	-27,597,000	-27,943,000	6,155,000	25,043,000	-20,919,000	-25,651,000	-26,376,000	-24,271,000	-19,134,000	-20,257,000	-19,328,000	-17,527,000	-14,172,000	-9,562,000	-5,125,000	-3,526,000	-1,430,000	-1,136,000	-1,150,000	-697,000	-1,059,000	-1,359,000	-1,267,000		-2,156,000	-3,534,000	-3,246,000	-3,450,000	33,015,000	-762,000	-301,000	-408,000	-1,794,000	-1,550,000	-130,000	30,000	-391,000	-815,000	-1,200,000	-207,000	-9,171,000	-1,028,000	-804,000	-1,020,000	-297,000	-1,312,000	-34,000	-1,824,000	-1,389,000	15,191,000	-1,025,000	2,570,000	1,131,000	3,173,000	3,365,000	12,636,000	-5,711,000	9,656,000	1,367,000	877,000	-3,133,000	-8,767,000	-10,182,000	-8,589,000	-83,564,000	-9,231,000	-9,066,000	-10,163,000	-59,316,000	-5,969,000	-4,346,000		6,560,163	6,560,163
yoy	-818.51%	-193.45%	31.92%	8.94%	-123.34%	-203.18%	9.33%	26.63%	36.47%	38.48%	35.01%	111.85%	277.13%	397.08%	891.05%	741.73%	345.65%	405.88%	35.03%	-16.41%	-9.23%		-50.88%	-61.54%	-60.97%		-106.53%	363.78%	978.41%	745.59%	-1940.30%	-50.84%	131.54%	-1460.00%	358.82%	90.18%	-89.17%	-114.49%	-95.74%	-20.72%	49.25%	-79.71%	2987.88%	-21.65%	2264.71%	-44.08%	-78.62%	-108.64%	-96.68%	-170.97%	-222.81%	378.76%	-130.46%	-79.66%	-119.80%	-67.14%	146.16%	1340.82%	82.29%	-210.14%	-113.43%	-110.21%	-96.25%	-5.03%	12.31%	-15.49%	40.88%	54.65%	108.61%		33.46%	-86.57%
qoq	88.97%	-15.20%	-1.24%	-553.99%	-75.42%	-219.71%	-18.45%	-2.75%	8.67%	26.85%	-5.54%	4.81%	10.28%	23.67%	48.21%	86.58%	45.35%	146.57%	25.88%	-1.22%	64.99%	-34.18%	-22.08%	7.26%			-38.99%	8.87%	-5.91%	-110.45%	-4432.68%	153.16%	-26.23%	-77.26%	15.74%	1092.31%	-533.33%	-107.67%	-52.02%	-32.08%	479.71%	-97.74%	792.12%	27.86%	-21.18%	243.43%	-77.36%	3758.82%	-98.14%	31.32%	-109.14%	-1582.05%	-139.88%	127.23%	-64.36%	-5.71%	-73.37%	-321.26%	-159.14%	606.36%	55.87%	-127.99%	-64.26%	-13.90%	18.55%	-89.72%	805.25%	1.82%	-10.79%	-82.87%	893.73%	37.34%
net income margin %																															93.68%	-38.92%	-15.36%	-20.84%	-72.69%	-56.88%	-4.77%	1.01%	-14.23%	-29.65%	-43.60%	-6.40%	-114.51%	-35.51%	-30.27%	-31.39%	-7.96%	-34.87%	-0.55%	-26.69%	-16.85%	50.15%	-9.72%	17.56%	8.05%	20.07%	23.92%	57.30%	-90.14%	52.17%	9.94%	5.72%
shares used in computing net income per share, basic	48,308	48,262	595	47,976	46,202	43,001
net income per share	-0.92	-0.48	-0.6	-0.58	0.13	0.58	-0.5	-0.61	-0.63	-0.58	-0.47	-0.51	-0.48	-0.44	-0.36	-0.24	-0.13	-0.09	-0.06	-0.05	-0.05	-0.04	-0.06	-0.08	-0.11		-0.058	-0.08	-0.07	-0.08	-0.008	-0.02	-0.01	-0.01	-0.04	-0.03	0	0	-0.01	-0.02
numerator, diluted:																																																																											-44,446,324	-44,446,324
adjustment for change in fair value of warrant liabilities						-43,792
adjusted numerator, diluted	-44,224	-23,403	-27,597	-27,943	6,155	-18,749																																																																					0.00%	0.00%
shares used in computing net income per share, diluted	48,308	48,262	503	47,976	46,202	44,102
research and development, net of grant reimbursement							18,731,000	23,603,000	24,969,000	22,120,000	17,652,000	18,526,000	16,948,000	14,906,000	10,342,000	8,041,000	3,901,000	2,529,000	399,000	591,000	544,000	-52,000	308,000	574,000
shares used in computing net income per share, basic and diluted							87	42,002	41,793	41,739	193	40,050	40,015	39,962	187	39,957	39,953	37,721	24,972	24,779	24,481	17,162	17,162	17,162	11,959
gain on sale of property and equipment																				-246,000	-100,000
cassava sciences, inc.
condensed statements of cash flows
cash flows from operating activities:
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation																	665	250
depreciation and amortization																	9	1				44	30	17	52
changes in operating assets and liabilities:
prepaid and other assets																	-2,236
operating lease right-of-use assets and liabilities																	31	25
accounts payable																	1,001	-47				46	300	201	125
accrued development expense																	1,743	834				259	23	87	-399
accrued compensation and benefits																	37	16						1
other current liabilities																	-44	-44				7	14	12	8
net cash from operating activities																	-7,445	-2,306				-1,925	-1,195	-604	-4,205
cash flows from investing activities:
purchase of property and equipment																	-73
proceeds from sale of property and equipment
net cash from investing activities																	-73					-18	-18	-18
cash flows from financing activities:
proceeds from exercise of stock options																	1,749	475
proceeds from exercise of common stock warrants																	692	692
proceeds from registered direct offering, net of issuance costs																	189,825	189,825
net cash from financing activities																	192,266	190,992							14,170
net increase in cash and cash equivalents																	184,748	188,686							9,965
cash and cash equivalents at beginning of period																	93,506	93,506				19,807	19,807	19,807	10,479
cash and cash equivalents at end of period																	278,254	282,192				17,804	18,534	19,125	20,444
other current assets																		185				-152	184	93	-92
supplemental cash flow information:
receivable from exercise of stock options																		1,271
non-cash stock-based compensation																						992	673	344	1,985
purchases of property and equipment																						-18	-18	-18
net cash from / (used in) investing activities
issuance costs from 2018 sale of common stock and warrants																						-60	-60	-60
net cash from / (used in) financing activities
net increase / (decrease) in cash and cash equivalents
statements of cash flows
proceeds from issuance of common stock and warrants, net of issuance costs
net cash (used in) / provided by financing activities																						-60	-60	-60
net (decrease) / increase in cash and cash equivalents																						-2,003		-682
net decrease in cash and cash equivalents																							-1,273
pain therapeutics, inc.
non-cash net interest income
purchases of marketable securities
sales of marketable securities
maturities of marketable securities
proceeds from issuance of common stock, net of issuance costs																									14,170
revenue:
program fee revenue																															35,244,000	1,958,000	1,959,000	1,958,000	2,468,000	2,725,000	2,724,000	2,724,000	2,724,000	2,725,000	2,724,000	2,724,000	2,724,000	2,724,000	2,524,000	2,524,000	3,587,000	3,587,000	3,587,000	3,587,000	3,587,000	3,587,000	3,587,000	3,587,000	3,587,000	6,551,000	6,550,000	6,550,000	6,550,000	6,550,000	6,550,000	6,550,000
total revenue																															35,244,000	1,958,000	1,959,000	1,958,000	2,468,000	2,725,000	2,724,000	2,973,000	2,747,000	2,749,000	2,752,000	3,236,000	8,009,000	2,895,000	2,656,000	3,249,000	3,729,000	3,763,000	6,236,000	6,835,000	8,244,000	30,294,000	10,547,000	14,639,000	14,056,000	15,810,000	14,065,000	22,054,000	6,336,000	18,510,000	13,746,000	15,326,000
yoy																															1328.04%	-28.15%	-28.08%	-34.14%	-10.16%	-0.87%	-1.02%	-8.13%	-65.70%	-5.04%	3.61%	-0.40%	114.78%	-23.07%	-57.41%	-52.47%	-54.77%	-87.58%	-40.87%	-53.31%	-41.35%	91.61%	-25.01%	-33.62%	121.84%	-14.59%	2.32%	43.90%
qoq																															1700.00%	-0.05%	0.05%	-20.66%	-9.43%	0.04%	-8.38%	8.23%	-0.07%	-0.11%	-14.96%	-59.60%	176.65%	9.00%	-18.25%	-12.87%	-0.90%	-39.66%	-8.76%	-17.09%	-72.79%	187.23%	-27.95%	4.15%	-11.09%	12.41%	-36.22%	248.07%	-65.77%	34.66%	-10.31%
weighted-average shares used for eps calculation																												45,345	45,247	45,127			44,999		44,753	44,601	44,777		44,160																								43,795	43,853	43,744,000	43,664		35,594	35,499	35,426,000		27,999	27,334,000
collaboration revenue																																						249,000	23,000	24,000	28,000	512,000	285,000	171,000	132,000	725,000	142,000	176,000	2,649,000	3,248,000	4,657,000	6,707,000	6,960,000	11,052,000	10,469,000	9,259,000	7,515,000	15,504,000	-214,000	6,960,000	7,196,000	8,776,000
revenue
operating expenses
weighted-average shares used for eps calculation																												45,345	45,247	45,127			44,999		44,753	44,601	44,777		44,160																								43,795	43,853	43,744,000	43,664		35,594	35,499	35,426,000		27,999	27,334,000
basic																											45,269				45,007			44,932				44,732					42,644			42,410	42,165	42,201	42,137	42,090	42,252	41,535	41,579	43,848	44,150	44,049	44,025	44,341	44,146	44,184	44,138	43,995
diluted																											45,269				45,208			44,932				44,756					42,644			42,410	42,165	42,201	42,137	42,090	43,857	43,021	41,579	45,388	45,676	45,655	45,180	45,591	45,475	45,221	45,258	45,505
weighted-average shares used for eps calculation																												45,345	45,247	45,127			44,999		44,753	44,601	44,777		44,160																								43,795	43,853	43,744,000	43,664		35,594	35,499	35,426,000		27,999	27,334,000
basic and diluted																																								44,631	44,190	43,124		42,703	42,663
net income per share	-0.92	-0.48	-0.6	-0.58	0.13	0.58	-0.5	-0.61	-0.63	-0.58	-0.47	-0.51	-0.48	-0.44	-0.36	-0.24	-0.13	-0.09	-0.06	-0.05	-0.05	-0.04	-0.06	-0.08	-0.11		-0.058	-0.08	-0.07	-0.08	-0.008	-0.02	-0.01	-0.01	-0.04	-0.03	0	0	-0.01	-0.02
basic and diluted																																									-0.03	0	-0.018	-0.02	-0.02
income before benefit from income taxes																																											-713,000	-1,028,000	-804,000	-1,020,000	-963,750	-1,675,000	-35,000	-2,145,000					1,131,000	3,173,000	3,365,000	12,636,000			3,977,000	2,590,000
benefit from income taxes																																															-825,000	-363,000	-1,000	-321,000											2,610,000	1,713,000
net income per share	-0.92	-0.48	-0.6	-0.58	0.13	0.58	-0.5	-0.61	-0.63	-0.58	-0.47	-0.51	-0.48	-0.44	-0.36	-0.24	-0.13	-0.09	-0.06	-0.05	-0.05	-0.04	-0.06	-0.08	-0.11		-0.058	-0.08	-0.07	-0.08	-0.008	-0.02	-0.01	-0.01	-0.04	-0.03	0	0	-0.01	-0.02
basic																																														-0.02		-0.03	0	-0.04	-0.04	0.37	-0.02	0.06	0.03	0.07
diluted																																														-0.02		-0.03	0	-0.04	-0.03	0.35	-0.02	0.06	0.02	0.07
milestone revenue																																																				20,000,000								5,000,000
interest and other income																																																							2,768,000	2,642,000	2,446,000	2,280,000	2,553,000	2,559,000	2,468,000	2,088,000	519,000	482,000	475,000	571,000
earnings per share
basic																																																									0.08	0.28	-0.13	0.22	0.03	0.02
diluted																																																									0.07	0.28	-0.12	0.21	0.03	0.02
income before provision (credit) for income taxes																																																											3,869,500	8,912,000
provision (credit) for income taxes																																																											894,750	-744,000
other income:
return to series c preferred stockholders for beneficial conversion feature																																																																										-14,231,000
loss available to common stockholders																																																															-6,884,250	-8,767,000	-10,182,000	-8,589,000	-97,795,000	-9,231,000	-9,066,000	-10,163,000	-73,547,000	-5,969,000	-4,346,000	-71,479,000
basic and diluted loss per share																																																															-0.07	-0.2		-0.2	-0.2	-0.26	-0.26		-0.135	-0.21
basic and diluted loss per common share																																																																	-230					-290			-160
operating expenses :
return to series c preferred stockholder for beneficial conversion feature
licensing fees
research and development:
total research and development expense
general and administrative:
total general and administrative expense
net income before income taxes
income tax expense
return to series c preferred shareholders for beneficial conversion feature
net income available to common shareholders																																																																											100,000	100,000
basic and diluted net income per share

We provide you with 20 years income statements for Cassava Sciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cassava Sciences stock. Explore the full financial landscape of Cassava Sciences stock with our expertly curated income statements.

The information provided in this report about Cassava Sciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.